Dysthymia (Persistent Depressive Disorder)

The short version

●Dysthymia (now persistent depressive disorder, PDD, in DSM-5-TR) is a chronic depressive condition lasting two or more years in adults — not the absence of severe depression but its own clinical entity.
●Often missed because patients present functional (work attendance, social roles maintained) and describe "this is just how I am" rather than a discrete illness episode.
●Pharmacotherapy response rates are LOWER than for major depressive disorder — fewer than half of PDD patients achieve remission with first-line SSRIs at adequate dose and duration.
●Combined psychotherapy plus pharmacotherapy outperforms either alone; CBASP (Cognitive Behavioral Analysis System of Psychotherapy) is the modality with the most specific evidence base for chronic forms.
●Ketamine's evidence base in PDD specifically is small, but real-world cohorts and case series show meaningful response in patients who haven't responded to adequate SSRI/SNRI trials.
●Diagnosis matters because the treatment plan differs: longer-duration therapy, lower expectations for response to first-line drugs, earlier consideration of augmentation or rapid-acting strategies like ketamine.

Clinical definition

DSM-5-TR defines persistent depressive disorder as depressed mood for most of the day, more days than not, for at least two years in adults (one year in children/adolescents), plus at least two of: poor appetite or overeating, insomnia or hypersomnia, low energy, low self-esteem, poor concentration, or hopelessness. The chronicity criterion (≥2 years) is what distinguishes PDD from MDD. Patients may have superimposed major depressive episodes ("double depression") or persist at sub-syndromal severity that meets PDD but not MDD criteria. ICD-10 codes this as F34.1 (dysthymic disorder); ICD-11 reorganizes it within mood disorders as a chronic depressive course pattern. The clinical implication of the duration criterion is significant — patients have often had years of unsuccessful treatment attempts before PDD is correctly identified, and they may underestimate their own symptom burden because the baseline has become normal to them.

How it differs from related conditions

vs. Major depressive disorder (MDD)

MDD requires a discrete 2-week episode of depressed mood + anhedonia + symptoms. PDD requires 2+ YEARS of milder depressed mood. Many patients meet both at different times — "double depression" describes PDD with superimposed MDD episodes. The duration criterion is the key separator; severity is not.

vs. Major depressive disorder, chronic specifier

DSM-5-TR allows MDD to be specified as "chronic" when episode lasts ≥2 years. The overlap with PDD is now substantial — DSM-5 essentially folded chronic MDD and dysthymia into PDD. Clinically, distinguish by severity (PDD often less severe baseline; chronic MDD often more severe sustained).

vs. Adjustment disorder with depressed mood

Adjustment disorder requires an identifiable stressor and resolves within 6 months of stressor offset. PDD has no required precipitant and is by definition chronic (≥2 years). Misdiagnosis in either direction is common when stressors are chronic and overlapping.

vs. Cyclothymic disorder

Cyclothymia involves alternating hypomanic and depressive symptoms below threshold for bipolar 2; PDD is unipolar depressive symptoms only. Patients with cyclothymia describe mood cycling; PDD patients describe a sustained low baseline. Distinct treatment implications (cyclothymia needs mood stabilizer assessment).

First-line treatments

SSRIs (sertraline, escitalopram, fluoxetine)

First-line pharmacotherapy. PDD-specific response rates are lower than in MDD — published trials show approximately 40-50% achieve clinical response and 25-35% achieve remission at adequate dose for at least 8 weeks. The lower response rate is itself diagnostic information: patients who plateau at "feeling somewhat better" rather than remission with SSRIs may need augmentation or alternative-mechanism options.

SNRIs (duloxetine, venlafaxine)

Second-line pharmacotherapy or first-line in patients with comorbid pain or fatigue. Mechanism (serotonin + norepinephrine) adds a noradrenergic dimension absent in pure SSRIs. Effect sizes in chronic depression trials are similar to SSRIs; some patients respond preferentially to one class. Tolerability profile differs (SNRIs more activating, more BP and discontinuation issues).

CBASP (Cognitive Behavioral Analysis System of Psychotherapy)

McCullough's CBASP is the psychotherapy with the most specific evidence base for chronic depression. It addresses the interpersonal patterns and cognitive-emotional rigidity characteristic of patients with very long depressive histories. Trials in PDD specifically (including Schramm and colleagues' work) show CBASP plus pharmacotherapy outperforms pharmacotherapy alone.

CBT and interpersonal psychotherapy (IPT)

Generic CBT and IPT both have established evidence in chronic depression, with effect sizes smaller than in acute MDD but real. Many patients have already had multiple unsuccessful CBT courses by the time PDD is identified; in those cases, switching modality (to IFS, schema therapy, or CBASP if available) is often more useful than another CBT round.

Atypical antipsychotic augmentation

Adjunctive aripiprazole or quetiapine XR at low doses can augment SSRI/SNRI response. The trials are primarily in TRD rather than PDD specifically, but the chronic depressive population overlaps substantially. Side-effect burden (weight, metabolic) is non-trivial; reserve for patients with adequate SSRI/SNRI trials who have plateaued.

Exercise and lifestyle intervention

Structured aerobic exercise has consistent evidence in depression including chronic forms — effect sizes comparable to medication monotherapy in some trials. Adherence is the practical barrier for patients with severe anhedonia and energy deficit. Start small (10-15 minute walks), titrate up. Sleep regularization and substance reduction (especially alcohol) have meaningful effects in PDD where the chronic course often involves accumulated lifestyle drift.

Light therapy (10,000 lux, morning)

Established in seasonal depression and increasingly evidenced in non-seasonal chronic depression. Mechanism: circadian phase advance + serotonergic modulation. 30 minutes morning exposure (within first hour of waking). Inexpensive, safe, often underused. Combination with medication is additive rather than redundant.

When standard treatments fail

PDD patients typically need a sequence of treatment trials over years before identifying what works. The conventional escalation: SSRI #1 at adequate dose for 8-12 weeks → switch to SSRI #2 or SNRI → augment with bupropion, lithium, or thyroid hormone → atypical antipsychotic augmentation → consider rapid-acting options (ketamine, esketamine) or neurostimulation (rTMS). Combined psychotherapy alongside should run continuously through this sequence — switching psychotherapy modality at the same point as switching medication is often productive. The pacing matters: patients with 10+ years of dysthymia have often had multiple incomplete trials (sub-therapeutic doses, premature discontinuation, no concurrent psychotherapy) that don't constitute true "failure" of the medication and may respond to a properly executed retrial.

Where ketamine fits

Ketamine in PDD is not first-line. It enters the picture after adequate trials of SSRI/SNRI plus psychotherapy fail to produce sustained remission — the same general criteria as treatment-resistant depression. PDD patients often experience the rapid-acting effect of ketamine as particularly striking because they have not felt symptom relief in years; some report a window of clear thinking and emotional reach within hours of the first session that they describe as "remembering what feeling normal was like." The clinical question is durability: PDD patients may need more frequent or longer-duration maintenance than discrete-episode MDD patients because the underlying chronicity tends to reassert. Pairing maintenance ketamine with sustained psychotherapy (CBASP, IFS, schema therapy) is the model with the most plausible mechanism for durable change in chronic depression.

Where this fits with Tovani

Tovani treats PDD when standard treatments have been adequately tried — usually meaning at least two SSRI or SNRI trials at adequate dose for 8+ weeks, plus a course of evidence-based psychotherapy. Eligibility screening captures medication and therapy history. For patients with very long histories (10+ years dysthymia), the physician often recommends longer induction (6-8 sessions rather than 4-6) and explicit pairing with concurrent psychotherapy because the chronicity raises the bar for durable response.

Check eligibility The science behind ketamine

Frequently asked

How do I know if I have dysthymia versus regular depression?

Time course is the key. Major depressive disorder is episodic — discrete episodes with periods of return to baseline between them. Dysthymia (PDD) is chronic — depressed mood most of the time for two or more years, without a clear "well" period. Many patients have both at different times. Your clinician makes the distinction based on history.

Why didn't my SSRI work for my dysthymia?

PDD response rates to first-line SSRIs are lower than in MDD — published trials show roughly 40-50% achieve clinical response and 25-35% achieve remission. Reasons include the underlying chronicity (less plasticity), accumulated comorbidities (chronic substance use, sleep disruption), and the fact that "response" in PDD often means partial improvement rather than full remission. A second SSRI, an SNRI, augmentation, or alternative-mechanism options like ketamine often outperform persistence with the first agent.

Is ketamine helpful for dysthymia specifically?

The trial evidence in PDD specifically is small, but real-world cohorts show meaningful response in patients who haven't responded to adequate SSRI/SNRI trials. Patients often describe the rapid-acting effect as particularly striking after years without feeling well. Durability is the open question — maintenance plans may need to be more sustained than for discrete-episode MDD.

Will I need therapy alongside ketamine?

Strongly recommended for chronic depression. The combined-treatment evidence (psychotherapy + medication) consistently outperforms either alone in PDD. CBASP has the most specific evidence base; CBT, IPT, IFS, and schema therapy are also reasonable choices depending on what fits your situation. Tovani encourages and helps connect patients with qualified therapists.

Will my dysthymia come back after ketamine?

For some patients yes, for others no — durability is variable. The underlying chronicity of PDD tends to reassert, which is why maintenance dosing alongside sustained psychotherapy is the typical long-term plan. Many patients experience long periods of remission with periodic booster sessions plus ongoing psychotherapy. The honest answer is that we cannot predict durability in any individual patient before they start.

References

Schramm E et al. 2025, BMJ Open — Psychotherapy versus pharmacotherapy or their combination in chronic depression — trial demonstrating superior outcomes with combined treatment, with CBASP as the psychotherapy modality with the strongest evidence base for chronic depressive presentations. (PMID 39971604)
Cipriani A et al. 2018, Lancet — Network meta-analysis of 21 antidepressants in adult depression — effect sizes and acceptability rankings inform first-line and sequencing choices in chronic depressive disorders including PDD. (PMID 29477251)
Murrough JW et al. 2013, American Journal of Psychiatry — Ketamine RCT in treatment-resistant depression — rapid antidepressant effect with relevance to chronic depressive presentations that have not responded to adequate trials of conventional antidepressants. (PMID 23982301)

Last reviewed by Dr. Ben Soffer, DO on May 27, 2026. This page is educational and not a substitute for clinical evaluation. A physician determines whether ketamine therapy is appropriate for your specific situation.